Gapping up
In reaction to strong earnings/guidance: SOL +9.8%, BZUN +4.7%, RYAAY +1.9%
M&A news: XNPT +57.7% (to be acquired by Arbor Pharma for $7.03/share), REXI +47.8% (to be acquired by C-III Capital Partners for $9.78/share ), NSPH +26.7% (Luminex increases purchase offer to acquire Nanosphere to $1.70/share from $1.35/share), ACTS +21.7% (receives prelim non-binding going private proposal from its former CEO to purchase Co for $2.00 per ADS), AIXG +14.1% (receives takeover offer from Fujian Grand Chip valued at EUR670 mln), MON +9.2% (Bayer (BAYRY) proposes to acquire Monsanto for $122 per share in cash), ONCS +4.8% (agrees to sell to a single healthcare dedicated institutional fund ~5.5 mln common shares at a price of $1.815/share), TLRD +4.2% (George Zimmer might be involved in purchasing back Men's Warehouse, according to NY Post)
Other news: RLYP +4.9% (reports new positive analyses of studies with Veltassa), VSLR +4.4% (closes tax equity investment fund with a new investor, with an aggregate funding commitment of $75 mln), NVS +2.3% (given strong Class I recommendation for Entresto in both US and EU heart failure guidelines), SGYP +1.5% (presents additional Phase 3 plecanatide data), GPRO +1.1% (still checking), BA +0.9% (order for one hundred 737 MAX 200's with VietJet Aviation, valued at ~$11.3 bln), MYL +0.7% (announces the U.S. launch of Doxycycline Hyclate Delayed-Release Tablets)
Analyst comments: OLED +4.1% (upgraded to Buy from Neutral at Goldman), SQ +3.3% (upgraded to Buy from Outperform at Credit Agricole), SPLS +2.7% (upgraded to Buy at BofA/Merrill), ATI +2% (upgraded to Buy at BofA/Merrill), P +1.9% (upgraded to Buy from Neutral at B. Riley & Co), AA +1.4% (upgraded to Buy from Neutral at BofA/Merrill), RDUS +1.2% (initiated with a Buy at H.C. Wainwright; tgt $55)